BR0110028A - Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica - Google Patents
Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnicaInfo
- Publication number
- BR0110028A BR0110028A BR0110028-9A BR0110028A BR0110028A BR 0110028 A BR0110028 A BR 0110028A BR 0110028 A BR0110028 A BR 0110028A BR 0110028 A BR0110028 A BR 0110028A
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- visceral pain
- chronic visceral
- ngf antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
USO DE ANTAGONISTAS-NGF PARA A PREVENçãO OU TRATAMENTO DE DOR VISCERAL CRÈNICA. Uso de um antagonista de fator de crescimento de nervo (NGF) para a fabricação de um medicamento pretendido para a prevenção ou tratamento de dor visceral crónica e co
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0004782A FR2807660A1 (fr) | 2000-04-13 | 2000-04-13 | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
PCT/EP2001/003490 WO2001078698A2 (en) | 2000-04-13 | 2001-03-26 | Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
US10/269,285 US20040071701A1 (en) | 2000-04-13 | 2002-10-11 | Use of NGF-antagonists for the prevention or treatment of chronic visceral pain |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0110028A true BR0110028A (pt) | 2003-06-03 |
Family
ID=32737514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0110028-9A BR0110028A (pt) | 2000-04-13 | 2001-03-26 | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040071701A1 (pt) |
EP (1) | EP1282421A2 (pt) |
JP (1) | JP2003530427A (pt) |
AU (1) | AU2001254746A1 (pt) |
BR (1) | BR0110028A (pt) |
CA (1) | CA2404117A1 (pt) |
FR (1) | FR2807660A1 (pt) |
WO (1) | WO2001078698A2 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
DK1401498T3 (da) * | 2001-05-30 | 2011-11-21 | Genentech Inc | Anti-NGF-antistoffer til behandlingen af forskellige sygdomme |
EP1541172A1 (en) * | 2002-08-09 | 2005-06-15 | Ajinomoto Co., Inc. | Remedy for intestinal diseases and visceral pain |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
DE60335957D1 (de) | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
WO2005000194A2 (en) * | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
KR101250818B1 (ko) | 2002-12-24 | 2013-04-15 | 리나트 뉴로사이언스 코프. | 항-ngf 항체 및 그것을 이용하는 방법 |
US7655231B2 (en) | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
MEP31508A (en) * | 2003-07-15 | 2010-10-10 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
NZ549990A (en) | 2004-04-07 | 2009-08-28 | Rinat Neuroscience Copr | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
US9315571B2 (en) | 2005-01-24 | 2016-04-19 | Elan Pharma International Limited | Specific binding members for NGF |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
MX2008013400A (es) | 2006-04-19 | 2008-11-10 | Astellas Pharma Inc | Derivado de azolcarboxamida. |
MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
DK2206707T3 (da) | 2007-10-24 | 2014-08-11 | Astellas Pharma Inc | Azolcarboxamidforbindelse eller salt deraf |
EA021284B1 (ru) | 2008-02-04 | 2015-05-29 | Лей Лайн Дженомикс С.П.А. | Антитела и их производные |
WO2010029497A1 (en) * | 2008-09-12 | 2010-03-18 | Pfizer Limited | Treatment of endometriosis |
US9040508B2 (en) * | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
MX2012002464A (es) | 2009-08-28 | 2012-03-14 | Rinat Neuroscience Corp | El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral. |
SG183983A1 (en) | 2010-03-17 | 2012-10-30 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
ES2910305T3 (es) | 2010-08-19 | 2022-05-12 | Zoetis Belgium S A | Anticuerpos anti-NGF y su uso |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
EP2731439A4 (en) | 2011-07-12 | 2014-12-03 | Merck Sharp & Dohme | TrkA KINASE INHIBITORS, COMPOSITIONS CONTAINING SAME, AND ASSOCIATED METHODS |
US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
EP2858501A4 (en) | 2012-05-22 | 2015-12-09 | Merck Sharp & Dohme | TRK-A KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
KR20150023679A (ko) | 2012-06-08 | 2015-03-05 | 그렌마크 파머수티칼스 에스. 아. | 아미노산 치환을 갖는 인간화된 항-TrkA 항체 |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
DK3102555T3 (da) | 2014-02-05 | 2021-08-09 | VM Oncology LLC | Sammensætninger af forbindelser og anvendelser deraf |
WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
EP3193874A4 (en) | 2014-09-17 | 2018-04-25 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
AU2019234213A1 (en) | 2018-03-12 | 2020-09-03 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992008483A1 (en) * | 1990-11-13 | 1992-05-29 | The Children's Medical Center Corporation | CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY |
AU3695295A (en) * | 1995-10-25 | 1997-05-15 | Queen's University At Kingston | Neurotrophin antagonists |
GB9525180D0 (en) * | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
KR20000052691A (ko) * | 1996-10-21 | 2000-08-25 | 스트라칸 그라함 | 뉴로트로핀 길항제 조성물 |
IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
-
2000
- 2000-04-13 FR FR0004782A patent/FR2807660A1/fr active Pending
-
2001
- 2001-03-26 EP EP01927818A patent/EP1282421A2/en not_active Withdrawn
- 2001-03-26 JP JP2001575999A patent/JP2003530427A/ja not_active Abandoned
- 2001-03-26 BR BR0110028-9A patent/BR0110028A/pt not_active IP Right Cessation
- 2001-03-26 AU AU2001254746A patent/AU2001254746A1/en not_active Abandoned
- 2001-03-26 CA CA002404117A patent/CA2404117A1/en not_active Abandoned
- 2001-03-26 WO PCT/EP2001/003490 patent/WO2001078698A2/en not_active Application Discontinuation
-
2002
- 2002-10-11 US US10/269,285 patent/US20040071701A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001078698A3 (en) | 2002-04-25 |
AU2001254746A1 (en) | 2001-10-30 |
US20040071701A1 (en) | 2004-04-15 |
CA2404117A1 (en) | 2001-10-25 |
FR2807660A1 (fr) | 2001-10-19 |
JP2003530427A (ja) | 2003-10-14 |
EP1282421A2 (en) | 2003-02-12 |
WO2001078698A2 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0110028A (pt) | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica | |
EP1425277B8 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
ATE300306T1 (de) | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung | |
CY1106733T1 (el) | Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη | |
WO2003074551A8 (en) | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | |
WO2004096122A3 (en) | Use of ngf antagonists and opioids for treating pain | |
EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
DE60233157D1 (de) | Zweikammer-herzschrittmacher-system zur diagnose und behebung von arrhythmien | |
BR0213358A (pt) | Uso de flibanserina | |
BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
DE60133389D1 (de) | Gabapentinanaloga für schlafstörungen | |
RS51069B (sr) | Upotreba oksikodona za tretiranje visceralnog bola | |
BR0209812A (pt) | Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas | |
BRPI0410049A (pt) | composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico | |
BR0213684A (pt) | Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas | |
IL159345A0 (en) | Active ingredient combination for pharmacological addictive substances or intoxicant therapy | |
IL198759A (en) | Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety | |
AP2002002501A0 (en) | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. | |
ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
ATE330599T1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt | |
BR9812531A (pt) | Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica | |
DK1420789T3 (da) | Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling | |
AU2003264297A1 (en) | Use of vanilloid receptor antagonists for the treatment of pain | |
SE9803623D0 (sv) | New therapeutic application | |
ID28817A (id) | Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |